ѻý

Alzheimer's Vaccines Are Back; Streamlining Prior Authorization; Rare APOE Variant

<ѻý class="mpt-content-deck">— News and commentary from the world of neurology and neuroscience
MedpageToday
Neuro Break over a computer rendering of neurons.

Interest in is back, according to interviews with 10 scientists and company executives. (Reuters)

Personalized using natalizumab (Tysabri) trough levels appeared feasible in relapsing-remitting multiple sclerosis in the first phase of the NEXT-MS trial. (Journal of Neurology, Neurosurgery, and Psychiatry)

Ubrogepant (Ubrelvy) halted migraine attacks better than placebo in a phase III trial. (The Lancet)

Neurologists offered suggestions to and improve care. (JAMA Neurology)

A higher glycemic index and glycemic load diet were linked with progression. (Annals of Neurology)

Food insecurity was linked with a , lower memory scores, and faster memory decline. (JAMA Network Open)

The rare APOE-R136S (Christchurch) variant APOE4-driven Alzheimer's pathologies in mouse and human neuron models. (Nature Neuroscience)

Intestinal inflammation was associated with age and in a cohort study. (Scientific Reports)

Sex differences in were linked with Alzheimer's disease. (Alzheimer's & Dementia)

Nanoplastics influenced Parkinson's disease-associated in mice. (Science Advances)

A brain-penetrant USP30 inhibitor in a Parkinson's disease mouse model. (Nature Communications)

The New York Times offered a close look at the lives of with autopsy evidence of chronic traumatic encephalopathy (CTE).

  • Judy George covers neurology and neuroscience news for ѻý, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more.